Novartis to Acquire Regulus Therapeutics for $1.7 Billion to Advance Kidney Disease Drug Development

Novartis AG is poised to advance the development of a novel kidney disease drug through a recent merger deal with Regulus Therapeutics. The potential first-in-class microRNA inhibitor is the central focus of this acquisition. The acquisition, valued at $1.7 billion, signals Novartis’ intent to further explore and potentially commercialize this new therapeutic approach to kidney disease. Regulus Therapeutics has been working on microRNA therapeutics, which modulate gene expression, representing a novel strategy for treating various diseases, including kidney disorders. Therefore, this deal may accelerate the drug’s journey through clinical trials and ultimately, possibly lead to its availability to patients.

Newsflash | Powered by GeneOnline AI
Date: May 1, 2025

Related posts:

Ignoring Intuition Increases Self-Blame, Study Finds Researchers Develop Method to Enhance Brainwave Monitoring During Deep Brain Stimulation Carbene Molecule Stabilized in Water, Validating 67-Year-Old Vitamin B1 Theory Healthcare Professionals Face Delays Integrating New Treatments; Insurance Coverage Lags Behind FDA Approval

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後